CNS Pharmaceuticals (NASDAQ:CNSP) Director Buys $34,009.00 in Stock

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Director Faith Charles purchased 7,100 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The shares were purchased at an average cost of $4.79 per share, with a total value of $34,009.00. Following the completion of the purchase, the director owned 7,100 shares in the company, valued at $34,009. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link.

CNS Pharmaceuticals Trading Up 7.3%

CNSP stock opened at $5.42 on Friday. CNS Pharmaceuticals, Inc. has a 12 month low of $1.90 and a 12 month high of $13.92. The company has a 50-day moving average price of $3.37 and a 200 day moving average price of $4.83. The stock has a market cap of $7.91 million, a PE ratio of -0.18 and a beta of 2.62.

CNS Pharmaceuticals (NASDAQ:CNSP) last released its quarterly earnings results on Thursday, May 14th. The company reported ($7.30) EPS for the quarter, topping analysts’ consensus estimates of ($8.82) by $1.52.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research note on Monday, April 20th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $20.00.

Institutional Investors Weigh In On CNS Pharmaceuticals

Several large investors have recently added to or reduced their stakes in CNSP. Armistice Capital LLC purchased a new stake in CNS Pharmaceuticals in the 2nd quarter valued at about $335,000. Ikarian Capital LLC purchased a new stake in CNS Pharmaceuticals in the 4th quarter valued at about $241,000. Finally, Boothbay Fund Management LLC purchased a new stake in CNS Pharmaceuticals in the 4th quarter valued at about $71,000. 14.02% of the stock is owned by hedge funds and other institutional investors.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.